glp-1 obesity drug updates today The popularity of drugs has exploded. Once a relatively obscure class of drugs prescribed for people with diabetes, GLP-1s have now shown an impressive ability to treat obesity, which affects Skyrocketing Cost of Obesity Drugs

Proceedings of the National Academy of Sciences, 113 (27), 7650-7654

When to Stop Discontinuation should be considered if IGF-1 exceeds 400 ng/mL on two consecutive measurements, if the patient develops new symptoms of carpal tunnel syndrome (a known GH excess sequela), or if diabetes control deteriorates with HbA1c rising more than 0.5 points from baseline

Studies have investigated NNMT inhibition in the context of obesity, metabolic dysfunction, lipid accumulation, and energy-expenditure models, with research also exploring effects on adipocyte differentiation and methylation pathways

The role of growth factors in diabetic peripheral neuropathy